Summary
Health Canada has authorized RYBELSUS® as the first GLP-1 pill to reduce the risk of heart attack and stroke in adults with type 2 diabetes. While the daily pill costs approximately $2542 per patient per year, it is widely covered by provincial health plans for eligible patients who have not seen success with metformin.
In a major expansion of diabetic care, Health Canada has officially authorized RYBELSUS® (semaglutide tablets) to reduce the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes.
While RYBELSUS® has been available since 2020 to manage blood sugar, this new authorization marks it as the first and only glucagon-like peptide-1 (GLP-1) receptor agonist in pill form proven to provide direct cardiovascular protection for high-risk patients in Canada.
Beyond Blood Sugar
Cardiovascular disease remains the second-leading cause of death in Canada, and for those living with type 2 diabetes, the risk of a life-altering heart event is significantly higher. Traditionally, cardiovascular protection in the GLP-1 class was only available via weekly injections.
The authorization is based on the results of the landmark SOUL trial, which involved over 9,600 participants. The study demonstrated that a 14 mg daily dose of oral semaglutide statistically reduced the risk of major adverse cardiovascular events (MACE) by 14% over a four-year period.
“This approval marks an important milestone for type 2 diabetes patients in Canada,” says Vince Lamanna, President of Novo Nordisk Canada Inc. “RYBELSUS is the first and only approved GLP‑1 in pill form in Canada that improves glycemic control and offers cardiovascular protection.”
Coverage and Cost
Despite being a high-demand medication, RYBELSUS® is increasingly accessible across the country. The current cost is approximately $2543 per patient per year.
For most Canadians, this cost is not paid entirely out of pocket:
- Provincial Coverage: RYBELSUS® is listed on most provincial formularies under “Limited Use” criteria for patients with type 2 diabetes.
- Private Insurance: Most private employer-based insurance plans provide coverage for RYBELSUS®, though co-pays vary.
- Patent Shifts: Interestingly, as of early 2026, the patent for some semaglutide formulations has begun to expire in Canada, paving the way for future generic versions that could further lower costs.
How to Take It
Unlike its injectable counterparts, RYBELSUS® is a daily tablet. However, its effectiveness depends on strict adherence to a specific routine: it must be taken on an empty stomach in the morning with no more than 4 ounces (half a cup) of plain water, followed by a 30-minute wait before eating or drinking anything else. If you miss a dose of RYBELSUS®, skip the missed dose and go back to your regular schedule.
By offering heart protection in a simple daily pill, Health Canada’s latest authorization provides a powerful new tool for Canadians looking to manage their diabetes while proactively defending their heart health.
Subscribe to The Health Insider newsletter for more evidence-based updates on Canadian medical breakthroughs.
~ Read more from The Health Insider ~
- Should You Take Berberine? What Health Canada and the Research Say
Berberine is trending as “nature’s Ozempic”, but what does Health Canada actually approve it for, and is it safe to take with your medications? - How Exercise Actually Grows Your BrainYour muscles feed your brain! Learn how to trigger the natural chemicals that protect your memory and sharpen your daily focus.
- What Is Hantavirus and Should Canadians Be Concerned?Hantavirus is rare but serious. Here’s what Canadians need to know about symptoms, how it spreads, and how to protect yourself.
- Radon Is the Leading Cause of Lung Cancer in Non-Smokers and Most Canadians Haven’t Tested for ItOne in five Canadian homes may have elevated radon but only 12% have ever tested. Here’s what you need to know.
- Canada Just Approved a New Alzheimer’s Drug. Here’s What You Need to KnowHealth Canada has approved a new Alzheimer’s drug that targets the disease itself, not just symptoms. Here’s what Canadians need to know.
- White, Brown, or Omega-3? Decoding The Egg AisleIs a $4 carton better than a $10 one? We dive into CFIA regulations to reveal which eggs are health powerhouses and which are just hype.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
